In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that the utilization of novel targets such as HER2 are not ready for prime time in the treatment of colorectal cancer.
Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER
© 2017 Imedex, LLC.
Advertisement